Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 94.77B |
| Revenue (ttm) | 45.93B |
| Net Income (ttm) | 9.11B |
| Shares Out | 1.21B |
| EPS (ttm) | 7.39 |
| PE Ratio | 15.02 |
| Forward PE | 9.54 |
| Dividend | 3.92 (5.02%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 140,576 |
| Average Volume | 1,664,458 |
| Open | 78.99 |
| Previous Close | 78.40 |
| Day's Range | 78.87 - 79.66 |
| 52-Week Range | 76.15 - 110.88 |
| Beta | 0.40 |
| RSI | 36.40 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Runnymede Capital Advisors, Inc. Buys 15,632 Shares of Sanofi SA (SNY)
Runnymede Capital Advisors, Inc. Buys 15,632 Shares of Sanofi SA (SNY)
Independence Bank of Kentucky Buys 76 Shares of Sanofi SA (SNY)
Independence Bank of Kentucky Buys 76 Shares of Sanofi SA (SNY)
Oakmark Global Select Fund Adds Sanofi (SNY) in Q4 2025
Oakmark Global Select Fund Adds Sanofi (SNY) in Q4 2025
Sanofi (SNY) Plans Enhanced Offer for Ocular Therapeutix
Sanofi (SNY) Plans Enhanced Offer for Ocular Therapeutix
Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more on SNY and OCUL stock prospects.
Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid
Ocular Therapeutix shares are trading higher ... Full story available on Benzinga.com
Ocular Therapeutix Launches On Rumors Sanofi Is Preparing A Bigger Bid
Shares of Ocular Therapeutix launched Thursday on reports Sanofi is preparing an improved bid to buy it.
Ocular Therapeutix (OCUL) Surges on Potential Sanofi Takeover Bid
Ocular Therapeutix (OCUL) Surges on Potential Sanofi Takeover Bid
Ocular surges on report of Sanofi buyout bid
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers
Sanofi Gains China NMPA Nod For Myqorzo And Redemplo In OHCM And FCS Treatments
(RTTNews) - Sanofi Winthrop Industrie announced that China's National Medical Products Administration (NMPA) has granted approval for two innovative Sanofi-licensed medicines. Myqorzo (aficamten) has ...
Press Release: Myqorzo and Redemplo approved in China
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi's long-term commitment to C...
Sanofi sees softness in U.S. vaccine demand in near term
Sanofi chief executive Paul Hudson said on Wednesday the U.S. is likely to see a slight weakness in vaccine demand this year due to misinformation and heightened scrutiny under the current administrat...
Sanofi: Information concerning the total number of voting rights and shares - December 2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Sandoz Secures European Commission Approval For Ondibta, A Biosimilar To Lantus, For Diabetes
(RTTNews) - Sandoz Group AG (SDZ.SW) announced that the European Commission has approved Ondibta (insulin glargine), a biosimilar to Sanofi's Lantus SoloStar, for the treatment of diabetes mellitus ac...
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.
Sanofi SA at JPMorgan Healthcare Conference Transcript
Sanofi SA at JPMorgan Healthcare Conference Transcript
Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sanofi (SNY) CEO Highlights Key Insights at JPMorgan Healthcare Conference
Sanofi (SNY) CEO Highlights Key Insights at JPMorgan Healthcare Conference
Dynavax gains on disclosure another bidder interested after deal announced
Dynavax (DVAX) stock rises after a mystery bidder shows interest despite Sanofi’s $2.2B, $15.50/share deal.
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi
--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025
Sanofi Wins EU Approval For Teizeild In Stage 2 Type 1 Diabetes
(RTTNews) - Sanofi (SNY) announced that the European Commission has approved Teizeild for adult and pediatric patients aged eight years and older with stage 2 type 1 diabetes.
Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes
Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D pa...
Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes
Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D pa...
BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence
BrightInsight Patient App improved treatment adherence and decreased discontinuation rate for for one of Sanofi and Regeneron's key biologic therapies.